Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Sexual medicine

Why stop a good thing? Discontinuing PDE5 inhibitors

Nature Reviews Urology volume 9, pages 483–485 (2012)Cite this article

Subjects

Reasons why men discontinue a medication that successfully addresses their erectile dysfunction have been investigated often. A recent study adds few new reasons for discontinuation, but does report which medical conditions result in men discontinuing due to PDE5 inhibitors not being able to restore their erectile function.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Althof, S. E. et al. Why do so many people drop out from auto-injection therapy for impotence? J. Sex Marital Ther. 15, 121–129 (1989).

    Article  CAS  Google Scholar 

  2. Kramarsky-Binkhorst, S. Female partner perception of Small-Carrion implant. Urology 12, 545–548 (1978).

    Article  CAS  Google Scholar 

  3. Al-Shaiji, T. F. & Brock, G. B. Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: Preference and adherence to treatment. Curr. Pharm. Des. 15, 3486–3495 (2009).

    Article  CAS  Google Scholar 

  4. Conaglen, H. M. & Conaglen, J. V. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J. Sex. Med. 9, 857–865 (2012).

    Article  Google Scholar 

  5. Giannitsas, K., Konstantinopoulos, A., Patsialis, C. & Perimenis, P. Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Prefer. Adherence 2, 149–155 (2008).

    PubMed  PubMed Central  Google Scholar 

  6. Padma-Nathan, H., Eardley, I., Kloner, R. A., Laties, A. M. & Montorsi, F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60 (Suppl. 2), 67–90 (2002).

    Article  Google Scholar 

  7. Carvalheira, A. A., Pereira, N. M., Maroco, J. & Forjaz, V. Dropout in the treatment of erectile dysfunction with PDE5: A study on predictors and a qualitative analysis of reasons for discontinuation. J. Sex. Med. doi:10.1111/j.1743-61092012.02787.x.

  8. Sato, Y. et al. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int. J. Urol. 14, 339–342 (2007).

    Article  CAS  Google Scholar 

  9. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy: 2007 position statement of The North American Menopause Society. Menopause 14 (3 Pt 1), 355–369 (2007). doi:10.1097/gme.0b013e318051718c.

  10. Althof, S. E. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int. J. Impot. Res. 14 (Suppl. 1), S99–S104 (2002).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sexual Health Research Unit, Waikato Clinical School, University of Auckland, Peter Rothwell Academic Centre, Waikato Hospital, Pembroke Street, Private Bag 3200, 3240, Hamilton, New Zealand

    Helen M. Conaglen & John V. Conaglen

Authors
  1. Helen M. Conaglen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John V. Conaglen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen M. Conaglen.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conaglen, H., Conaglen, J. Why stop a good thing? Discontinuing PDE5 inhibitors. Nat Rev Urol 9, 483–485 (2012). https://doi.org/10.1038/nrurol.2012.165

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2012.165

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer